The European Commission Has Granted Orphan Drug Designation To ALX Oncology's Evorpacept For Gastric Cancer, Includes Gastric Cancer And Gastroesophageal Junction Adenocarcinoma
Portfolio Pulse from Benzinga Newsdesk
The European Commission has granted Orphan Drug Designation to ALX Oncology's Evorpacept for the treatment of gastric cancer, including gastric cancer and gastroesophageal junction adenocarcinoma.
June 26, 2023 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ALX Oncology's Evorpacept receives Orphan Drug Designation from the European Commission for gastric cancer treatment, potentially boosting the company's market position.
The Orphan Drug Designation granted by the European Commission is a significant milestone for ALX Oncology and its product Evorpacept. This designation provides various benefits, including market exclusivity, reduced regulatory fees, and access to grants, which can help the company establish a strong market position in the gastric cancer treatment segment. As a result, this news is likely to have a positive short-term impact on ALX Oncology's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100